✦ LIBER ✦

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

✍ Scribed by Klimek, V. M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas, K.; Wright, J. J.; Pandolfi, P. P.; Nimer, S. D.

Book ID: 117993210
Publisher: American Association for Cancer Research
Year: 2008
Tongue: English
Weight: 188 KB
Volume: 14
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-07-0318

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of Oral Posaconazole in

Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome

✍ Dr. Gopal Krishna; Dr. Malaz AbuTarif; Dr. Fengjuan Xuan; Ms. Monika Martinho; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB

Cognitive impairment, fatigue, and cytok

Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome

✍ Christina A. Meyers; Maher Albitar; Elihu Estey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

Predictors and outcome of acute kidney i

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Amit Lahoti; Hagop Kantarjian; Abdulla K. Salahudeen; Farhad Ravandi; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Phase I trial of sodium salicylate in pa

Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

✍ Virginia M. Klimek; Emily K. Dolezal; Larry Smith; Gerald Soff; Stephen D. Nimer 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 198 KB

Gemtuzumab, fludarabine, cytarabine, and

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

✍ Apostolia Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (aml). the fludarabine and cytarabine (ara-c) regimen is active in these patients. resistance to gemtuzumab is associated with blast multidrug resistance (mdr). the objectives of th

Association of anemia and cognitive dysf

Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome

✍ Susan M. Wood; Christina A. Meyers; Stefan Faderl; Hagop M. Kantarjian; Sherry A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB 👁 3 views